With decades of leadership in fertility clinic management, clinical care and scientific research, ZyMōt Fertility’s Scientific Advisory Team (SAT) provides valuable guidance and support to our internal technical and business teams, as well as management. To support our customers, the SAT is available for training insights, data analysis, troubleshooting and more. If you are a clinic or academic researcher interested in pursuing a study involving ZyMōt devices, the SAT will lead you through our process for developing study designs, proposals and agreements. 

Marlane Angle, PhD, HCLD/CC (ABB)

Marlane received her PhD in Physiology from Auburn University in 1983.  She completed two NIH-funded postdoctoral fellowships at the University of Texas Health Science Center, San Antonio, TX, and Southwestern Medical School, Dallas, TX. She trained in IVF at the University of California, San Francisco, became a High Complexity Laboratory Director in 1995 and has directed IVF programs in Albuquerque, NM;  Asheville, NC; Greensboro, and Winston-Salem, NC; Las Vegas, NV; Little Rock, AR; Phoenix, AZ; Rochester, NY; San Francisco, CA; and Seattle, WA. She has worked as a consultant with multiple companies, including Irvine Scientific, Previvo Genetics, DxNow/ZyMōt Fertility and the World Egg Bank. Marlane also teaches in both the Masters and PhD programs at Eastern Virginia Medical School. She has published more than 70 papers, abstracts and chapters, and is one of the founders, and currently President of the Board of Directors, for the Southwest Embryology Summit. View Dr. Marlane Angle on LinkedIn.

Mary Mahony, PhD, HCLD (AAB)

Mary has over 35 years of experience as a healthcare leader, respected for advancing patient care with science in Reproductive Medicine and Endocrinology. She completed her PhD training jointly at Old Dominion University and the Jones Institute at Eastern Virginia Medical School (EVMS). During an Andrew Mellon Foundation postdoctoral fellowship, she focused her preclinical and clinical research on human sperm pre-fertilization capacitation events on the cellular level, including intracellular signaling occurring during hyperactivated motility, acrosome reaction and sperm-zona binding. Mary split her professional career between academia and the pharmaceutical/biotechnology industry. She rose to the rank of Associate Professor and Division Director, Reproductive Sciences, in the Department of Obstetrics and Gynecology at EVMS, and adjunct Associate Professor in the Department of Biological Sciences at ODU. She maintained a fully-supported research program with funding from NIH/NICHD, foundations and pharmaceutical/biotech companies, mentored the research efforts of graduate students and reproductive endocrinology fellows, and was certified as a High Complexity Laboratory. Upon leaving academia, Mary spent 20 years in pharmaceutical industry in positions of increasing responsibilities, the last at EMD Serono as Vice President, Fertility and Endocrinology, US Medical Affairs, where she was responsible for leading the medical team and its medical strategy for both pharmaceutical products and their devices and IVF laboratory medical devices. She has authored/co-authored more than 53 full publications in peer-reviewed journals with 103 published abstracts presented at national/international meetings. View Dr. Mary Mahony on LinkedIn.

Cynthia Hudson

Cynthia is an accomplished laboratory and management professional with over 20 years’ experience in reproductive technology. She founded a consulting company in 2004 and advises fertility clinics on compliance, lab design and construction, management, and staffing. She built and operated her own IVF center and launched two licensed medical practices. She is a co-founder of Kindbody, a groundbreaking firm designed to re-invent fertility care from the ground up, combining best-in-class technology, clinical excellence, and accessible pricing – connecting the full patient experience in one, intuitive platform. Cynthia is a seasoned and multi-faceted embryologist and medical technologist who holds a Master of Science degree in Clinical Embryology from the University of Leeds, England. She is a member of many professional organizations and has co-authored many papers in the field. She is an advisor to a wide range of corporate clients and ­clinical IVF programs domestically and internationally, and her work has been featured in presentations at ASRM and ESHRE. View Cynthia Hudson on LinkedIn.

Shelley Amster

Shelley is a senior life science executive with over 45 years of experience in research and clinical andrology, IVF, male infertility, female health, and biotech. After 16 years as an andrologist and embryologist, primarily at Yale and Tufts Universities, Shelley moved into industry. In 2008, she founded ShelleyCO, a life science business development consulting firm. Shelley is on several emerging life science companies’ boards, and a business and scientific advisor for several others. Shelley is a recognized leader in high quality conference production, developing several annual life science programs creating interactive dialogue on cutting edge topics incorporating her KOL network. View Shelley Amster on LinkedIn.

Alison Coates, PhD, HCLD (ABB)

Dr. Coates is currently the Laboratory Director at ORM Fertility in Portland, Oregon. She began her Embryology career in the United Kingdom in 1987. She graduated from Hull University with a BSc in Zoology, specializing in murine embryology and received her PhD in Genetics from Kent University in the UK. With over thirty years of experience, Dr. Coates has seen many changes in the world of IVF. She worked as an embryologist at the Hammersmith Hospital, London (where the world’s first clinical PGD cases were performed), at Leeds General Infirmary in the north of England, and in the Middle East, before settling in Portland in 1999 to create and direct the Reproductive Medicine Laboratory at ORM Fertility. Her research interests include mosaicism in blastocysts, defining which IVF patients benefit from preimplantation genetic screening for aneuploidy (PGT-A), sperm quality and its effect on embryonic aneuploidy and best practices for transfer of PGT-A screened embryos (fresh vs. frozen). Dr Coates has led several RCTs in the field of IVF, most noteworthy to determine the best transfer strategy for PGT-A screened embryos published in 2017. View Alison Coates on LinkedIn.